Browsing by Author "Beş, Cemal"
Now showing 1 - 8 of 8
- Results Per Page
- Sort Options
Publication An observational study from the perspective of rheumatology in the management of patients with psoriatic arthritis in Turkey - LOOP study(Wiley, 2021-09-01) Dalkılıç, Ediz; Solmaz, Dilek; Küçükşahin, Orhan; Çapkın, Erhan; Derin, Mehmet Emin; Arslan, Didem; Noyan, Fatih; Coşkun, Nihan Belkıs; Murat, Sadiye; Şendur, Ömer Faruk; Melikoğlu, Meltem Alkan; Gürsoy, Savaş; Kaya, Taciser; Şahin, Ali; Karkucak, Murat; Pırıldar, Timur; Terzioğlu, Mustafa Ender; Beş, Cemal; Akar, Servet; DALKILIÇ, HÜSEYİN EDİZ; COŞKUN, BELKIS NİHAN; Bursa Uludağ Üniversitesi/Tıp Fakültesi.; CMF-4757-2022; ICV-9647-2023Publication Are there any clues to predict bamboo spine in axial spondyloarthritis?(Wiley, 2020-10-01) Atagündüz, Pamir; Kiraz, Sedat; Akar, Servet; Küçükşahin, Orhan; Erden, Abdulsamet; Beş, Cemal; Kılıç, Levent; Karadağ, Ömer; Kaşifoğlu, Timuçin; Emmüngil, Hakan; Çınar, Muhammet; Kimyon, Gezmis; Yazısız, Veli; Ateş, Aşkın; Ersözlü, Emine Duygu; Gonullu, Emel; Mercan, Rıdvan; Ertenli, İhsan; Kalyoncu, Umut; Yağız, Burcu; YAĞIZ, BURCU; Coşkun, Nihan; COŞKUN, BELKIS NİHAN; Bursa Uludağ Üniversitesi/Tıp Fakültesi; CLH-7318-2022Item Assessment of damage and prognosis in patients with adult iga vasculitis: Retrospective multicentered cohort study(Bmj Publishing Group, 2017-06) Alibaz, Öner; Omma, Ahmet; Sarı, Alper; Karadağ, Ömer; Cansu, Döndü Üsküdar; Beş, Cemal; Yıldız, Fatih; Yılmaz, Sema; Balkarlı, Ayşe; Üreyen, S.; Direskeneli, Haner; Öksüz, Mustafa Ferhat; Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı.Publication Diagnostic dilemma of paraneoplastic arthritis: Case series(Wiley-blackwell, 2014-07-01) Kısacık, Bünyamin; Onat, Ahmet M.; Kaşifoğlu, Timuçin; Pehlivan, Yavuz; Pamuk, Ömer N.; Dönmez, Salim; Bilge, Sule Y.; Yilmaz, Sedat; Erdem, Hakan; Mercan, Ridvan; Özturk, Mehmet A.; Beş, Cemal; Soy, Mehmet; Erten, Sukran; Çobankara, Veli; Senel, Soner; Öner, Fatma A.; Direskeneli, Haner; Yılmaz, Sema; Yazıcı, Ayten; Emmungil, Hakan; Aksu, Kenan; Kul, Seval; Çetin, Gozde Y.; Sayarlıoğlu, Mehmet; DALKILIÇ, HÜSEYİN EDİZ; 0000-0002-6265-5227; 0000-0003-1537-2192; 0000-0003-1096-7306; 0000-0003-1710-7018; 0000-0003-0717-8365; 0000-0003-2598-5806; 0000-0002-4839-3777; 0000-0003-2167-4509; 0000-0001-5184-4404; JUV-4187-2023; JFJ-3399-2023; W-3342-2017; AAT-3636-2020; AAG-7687-2020; IZE-6133-2023; AAG-8227-2021; AAR-2072-2020; AAD-1796-2021; HLH-8218-2023; J-9960-2019; AAS-5508-2020; AAD-5233-2020Objectives: Paraneoplastic arthritis (PA) may mimic rheumatic diseases. While presenting the demographic and laboratory features of the patients diagnosed with PA, this study also aims to provide possible appropriate tools to differentiate the PA cases from early rheumatoid arthritis (ERA).Methods: Sixty-five patients with PA (male/female: 43/22) from 15 different rheumatology clinics and 50 consecutive patients with ERA (male/female: 13/37) fulfilling the 2010 American College of Rheumatology (ACR) criteria for the diagnosis if the RA from Gaziantep Rheumatology Early Arthritis Trial (GREAT) as controls who were diagnosed at least 12 months before, were enrolled into study.Results: Mean ages of the patients with PA and ERA were 50.2 +/- 15.3, and 42.7 +/- 12.3, respectively, and the mean ages of the patients with PA were significantly higher than the ERA. Unlike the ERA patients, in our case series PA was predominantly observed among males. Oligoarthritis was significantly higher in solid tumors in contrast to ERA (P = 0.001). Polyarthritis and symmetric arthritis were significantly higher in the ERA group in contrast to all malignancies (P = 0.001). Rheumatoid factor (RF) and anticyclic citrullinated peptide antibody (anti-CCP) positivity were significantly higher in the ERA group (each P = 0.001). Lactic dehydrogenase levels of hematologic malignancies were significantly higher than other groups (each, P = 0.001).Conclusions: ERA patients had more symmetric joint involvement than PA; laboratory markers could be also an alternative where there is high RF and anti-CCP positivity with antibody levels among the ERA patients. Finally, the demographic features can be used as differentiatingPublication Disease activity indices and body mass index: Cross-sectional analysis of a large psoriatic arthritis cohort(Wiley, 2015-10-01) Kalyoncu, Umut; Bayndar, Ozun; Yilmazer, Barış; Dalkılıç, Hüseyin Ediz; Aksu, Kenan; Öksüz, Mustafa Ferhat; Tarhan, E. Figen; Can, Meryem; Küçükşahin, Orhan; Kimyon, Gezmiş; Akyol, Lütfi; Onat, Ahmet Mesut; Kısacık, Bünyamin; Erden, Abdülsamet; Omma, Ahmet; Bakırlı, Duygu Ersözlü; Özişler, Cem; Gönüllü, Emel; Pehlevan, Seval; Solmaz, Dilek; Çınar, Muhammet; Çetin, Gözde; Tufan, Abdurrahman; Tufan, Müge Aydın; Kılıç, Levent; Erten, Şükran; Kaşifoğlu, Timuçin; Kobak, Şenol; Şenel, Soner; Akar, Servet; Özgen, Metin; Kasapoğlu-Günal, Esen; Yazısız, Veli; Yılmaz, Sedat; Dönmez, Salim; Doğan, İsmail; Köseoğlu, Hamide Kart; Erbasan, Funda; Yıldız, Fatih; Beş, Cemal; Balkarlı, Ayşe; Şahin, Ali; Mercan, Rıdvan; Arslan, Fatoş; Doğru, Atalay; Pay, Salih; Yavuz, Şule; Çakır, Necati; Kabasakal, Yasemin; Aydın, Sibel Z.; DALKILIÇ, HÜSEYİN EDİZ; CMF-4757-2022Publication Interim analysis of baseline characteristics and preferences of administration route of rheumatoid arthritis patients who are bio-naive or switched between advanced ra treatments; a multicenter, prospective, observational study(Wiley, 2018-09-01) Direskeneli, Haner; Karadağ, Ömer; Ateş, Aşkın; Tufan, Abdurrahman; İnanç, Nevsun; Koca, Süleyman Serdar; Çetin, Gözde Yıldırım; Akar, Servet; Çınar, Muhammet; Yılmaz, Sedat; Yılmaz, Neslihan; Dalkılıç, Ediz; Beş, Cemal; Özbalkan, Zeynep; Yılmazer, Bariş; Şahin, Ali; Ersözlü, Emine Duygu; Tezcan, Mehmet Engin; Şen, Nesrin; Keser, Gökhan; Tansoker, İlkan; Hacıbedel, Fatma Başak; Helvacıoğlu, Kerem; Günay, Levent Mert; DALKILIÇ, HÜSEYİN EDİZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi; CMF-4757-2022Publication Leflunomide as a concomitant dmard choice for the biological treatment era of rheumatoid arthritis(Wiley, 2018-09-01) Kimyon, Gezmiş; Kiraz, Sedat; Ertenli, İhsan; Küçükşahin, Orhan; Dalkılıç, Ediz; Beş, Cemal; Kanitez, Nilüfer Alpay; Kaşifoğlu, Timuçin; Emmungil, Hakan; Coşkun, Belkıs Nihan; Yağız, Burcu; Koca, Süleyman Serdar; Çınar, Muhammet; Ateş, Askin; Akar, Servet; Bakırlı, Duygu Ersözlü; Yazısız, Veli; Bilge, Nazife Şule Yaşar; Tufan, Müge Aydın; Mercan, Rıdvan; Karadağ, Ömer; Keleşoğlu, Ayşe Bahar; Gercik, Onay; Öz, Burak; Akar, Zeynel Abidin; Yılmaz, Sedat; Turan, Sezin; Pehlivan, Yavuz; Terzioğlu, Ender; Kılıç, Levent; Erten, Şükran; Tekgöz, Emre; Taşçılar, Koray; Kalyoncu, Umut; DALKILIÇ, HÜSEYİN EDİZ; COŞKUN, BELKIS NİHAN; YAĞIZ, BURCU; PEHLİVAN, YAVUZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Ramotoloji Bölümü; 0000-0003-0298-4157; JQW-5031-2023; AAG-7155-2021; AAG-8227-2021; CMF-4757-2022Publication Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic(TÜBİTAK, 2021-01-01) Kalyoncu, Umut; Pehlivan, Yavuz; Akar, Servet; Kaşifoğlu, Timuçin; Kimyon, Gezmiş; Karadağ, Ömer; Dalkılıç, Ediz; Ertenli, Ali İhsan; Kılıç, Levent; Ersözlü, Duygu; Beş, Cemal; Emmungil, Hakan; Mercan, Rıdvan; Ediboğlu, Elif Durak; Kanıtez, Nilüfer; Bilgin, Emre; Çolak, Seda; Koca, Süleyman Serdar; Gönüllü, Emel; Küçükşahin, Orhan; Coşkun, Nihan; Yağız, Burcu; Kiraz, Sedat; PEHLİVAN, YAVUZ; DALKILIÇ, HÜSEYİN EDİZ; COŞKUN, BELKIS NİHAN; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.; 0000-0002-3734-1242; 0000-0003-1372-1555; 0000-0001-5184-4404; 0000-0003-1185-5816; 0000-0002-2260-4660; 0000-0003-4995-430X; 0000-0002-6990-4206; W-7332-2019; AAK-7851-2021; AAD-5448-2019; AAZ-5845-2021; AAG-8227-2021; C-8092-2015; JQW-5031-2023; GZA-3287-2022Background/aim: To evaluate treatment adherence and predictors of drug discontinuation among patients with inflammatory arthritis receiving bDMARDs within the first 100 days after the announcement of the COVID-19 pandemic. Materials and methods: A total of 1871 patients recorded in TReasure registry for whom advanced therapy was prescribed for rheumatoid arthritis (RA) or spondyloarthritis (SpA) within the 3 months (6-9 months for rituximab) before the declaration of COVID-19 pandemic were evaluated, and 1394 (74.5%) responded to the phone survey. Patients' data regarding demographic, clinical characteristics and disease activity before the pandemic were recorded. The patients were inquired about the diagnosis of COVID-19, the rate of continuation on bDMARDs, the reasons for treatment discontinuation, if any, and the current general disease activity (visual analog scale, [VAS]). Results: A total of 1394 patients (493 RA [47.3% on anti-TNF] patients and 901 SpA [90.0% on anti-TNF] patients) were included in the study. Overall, 2.8% of the patients had symptoms suggesting COVID-19, and 2 (0.15%) patients had PCR-confirmed COVID-19. Overall, 18.1% of all patients (13.8% of the RA and 20.5% of the SpA; p = 0.003) discontinued their bDMARDs. In the SpA group, the patients who discontinued bDMARDs were younger (40 [21-73] vs. 44 years [20-79]; p = 0.005) and had higher general disease activity; however, no difference was relevant for RA patients. Conclusion: Although the COVID-19 was quite uncommon in the first 100 days of the pandemic, nearly one-fifth of the patients discontinued bDMARDs within this period. The long-term effects of the pandemic should be monitored.